

DAFTAR PUSTAKA

- AgoulNIK, I.U., Vaid, A., Bingman, W.E., Erdeme, H., Frolov, A., Smith, C.L., *et al.*, 2005. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. *Cancer Res.* 65: 7959–7967. doi:10.1158/0008-5472.CAN-04-3541
- Ahmad, R., Shihab, P.K., Jasem, S., & Behbehani, K., 2014. FSL-1 induces MMP-9 production through TLR-2 and NF- κ B /AP-1 signaling pathways in monocytic THP-1 cells. *Cell. Physiol. Biochem.* 34: 929–942. doi:10.1159/000366310
- Al-Khalil, S., Boothe, D., Durdin, T., Sunkara, S., Watkins, P., Yang, S., *et al.*, 2016a. Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review. *Int. Urol. Nephrol.* 48: 91–97. doi:10.1007/s11255-015-1146-2
- Al-Khalil, S., Ibilbor, C., Cammack, J.T., & de Riese, W., 2016b. Association of prostate volume with incidence and aggressiveness of prostate cancer. *Res. Reports Urol.* 8: 201–205. doi:10.2147/RRU.S117963
- Al-Sowayan, B.S., Al-Shareeda, A.T., & Al-Hujaily, E.M., 2019. Exosomes, cancer's little army. *Stem Cell Investig.* 6: 1–9. doi:10.21037/sci.2019.03.02
- Andres, S.A., Bickett, K.E., Alatum, M.A., Kalbfleisch, T.S., Brock, G.N., & Wittliff, J.L., 2015. Interaction between smoking history and gene expression levels impacts survival of breast cancer patients. *Breast Cancer Res. Treat.* 152: 545–556. doi:10.1007/s10549-015-3507-z
- Ang, M., Rajcic, B., Foreman, D., Moretti, K., & O'Callaghan, M.E., 2016. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL. *BJU Int.* 117: 68–75. doi:10.1111/bju.13411
- Arai, K., Lee, S.R., & Lo, E.H., 2003. Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. *Glia* 43: 254–264. doi:10.1002/glia.10255
- Augello, M.A., Den, R.B., & Knudsen, K.E., 2014. AR function in promoting metastatic prostate cancer. *Cancer Metastasis Rev.* 33: 399–411. doi:10.1016/j.physbeh.2017.03.040
- Babichenko, I.I., Andriukhin, M.I., Pulbere, S., & Loktev, A., 2014. Immunohistochemical expression of matrix metalloproteinase-9 and inhibitor of matrix metalloproteinase-1 in prostate adenocarcinoma. *Int. J. Clin. Exp. Pathol.* 7: 9090–9098.
- Baig, F.A., Hamid, A., Mirza, T., & Syed, S., 2015. Ductal and acinar adenocarcinoma of prostate: Morphological and immunohistochemical characterization. *Oman Med. J.* 30: 162–166. doi:10.5001/omj.2015.36
- Barillari, G., 2020. The impact of matrix metalloproteinase-9 on the sequential steps of the metastatic process. *Int. J. Mol. Sci.* 21: 1–29. doi:10.3390/ijms21124526

- Bhindi, A., Bhindi, B., Kulkarni, G.S., Hamilton, R.J., Toi, A., van der Kwast, T.H., *et al.*, 2017. Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort. *J. Can. Urol. Assoc.* 11: 41–46. doi:10.5489/cuaj.4031
- Bhome, R., Del Vecchio, F., Lee, G.H., Bullock, M.D., Primrose, J.N., Sayan, A.E., *et al.*, 2018. Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer. *Cancer Lett.* 420: 228–235. doi:10.1016/j.canlet.2018.02.002
- Biswas, M.H.U., Du, C., Zhang, C., Straubhaar, J., Languino, L.R., & Balaji, K.C., 2010. Protein kinase D1 inhibits cell proliferation through matrix metalloproteinase-2 and matrix metalloproteinase-9 secretion in prostate cancer. *Cancer Res.* 70: 2095–2104. doi:10.1158/0008-5472.CAN-09-4155
- Bobbili, M.R., Mader, R.M., Grillari, J., & Dellago, H., 2017. OncomiR-17-5p: Alarm signal in cancer? *Oncotarget* 8: 71206–71222. doi:10.18632/oncotarget.19331
- Boca, S., Gulei, D., Zimta, A.A., Onaciu, A., Magdo, L., Tigu, A.B., *et al.*, 2019. Nanoscale delivery systems for microRNAs in cancer therapy. *Cell. Mol. Life Sci.* doi:10.1007/s00018-019-03317-9
- Boerrigter, E., Groen, L.N., Van Erp, N.P., Verhaegh, G.W., & Schalken, J.A., 2019. Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. *Expert Rev. Mol. Diagn.* 0: 1. doi:10.1080/14737159.2019.1675515
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., & Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* 68: 394–424. doi:10.3322/caac.21492
- Bruyninckx, R., Buntinx, F., Aertgeerts, B., & Van Casteren, V., 2003. The diagnostic value of macroscopic haematuria for the diagnosis of urological cancer in general practice. *Br. J. Gen. Pract.* 53: 31–35.
- Buyyounouski, M.K., Choyke, P.L., McKenney, J.K., Sartor, O., Sandler, H.M., Amin, M.B., *et al.*, 2017. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA. Cancer J. Clin.* 67: 245–253. doi:10.3322/caac.21391
- Carmona Echeverria, L.M., Drudge-Coates, L., Wilkins, C.J., & Muir, G.H., 2012. Bone Scan Is of Doubtful Value as a First Staging Test in the Primary Presentation of Prostate Cancer. *ISRN Oncol.* 2012: 1–6. doi:10.5402/2012/585017
- Carver, B.S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandralapaty, S., *et al.*, 2011. Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. *Cancer Cell* 19: 575–586. doi:10.1016/j.ccr.2011.04.008
- Catalona, W.J., Richie, J.P., Ahmann, F.R., Hudson, M.A., Scardino, P.T., Flanigan, R.C., *et al.*, 2017. Comparison of Digital Rectal Examination and

- Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men. *J. Urol.* 197: S200–S207. doi:10.1016/j.juro.2016.10.073
- Ceylan, C., Doluoglu, O.G., Aglamis, E., & Baytok, O., 2014. Comparison of 8, 10, 12, 16, 20 cores prostate biopsies in the determination of prostate cancer and the importance of prostate volume. *J. Can. Urol. Assoc.* 8: 6–10. doi:10.5489/cuaj.510
- Chen, F.Z., & Zhao, X.K., 2013. Prostate cancer: Current treatment and prevention strategies. *Iran. Red Crescent Med. J.* 15: 279–284. doi:10.5812/ircmj.6499
- Chen, J.S., Wang, Q., Fu, X.H., Huang, X.H., Chen, X.L., Cao, L.Q., *et al.*, 2009. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. *Hepatol. Res.* 39: 177–186. doi:10.1111/j.1872-034X.2008.00449.x
- Chen, M., Xu, R., Rai, A., Suwakulsiri, W., Izumikawa, K., Ishikawa, H., *et al.*, 2019. Distinct shed microvesicle and exosome microRNA signatures reveal diagnostic markers for colorectal cancer. *PLoS One* 14: 1–21. doi:10.1371/journal.pone.0210003
- Cheng, C.Y., Hsieh, H.L., Hsiao, L. Der, & Yang, C.M., 2012. PI3-K/Akt/JNK/NF- κ B is essential for MMP-9 expression and outgrowth in human limbal epithelial cells on intact amniotic membrane. *Stem Cell Res.* 9: 9–23. doi:10.1016/j.scr.2012.02.005
- Chien, T.M., Lu, Y.M., Geng, J.H., Huang, T.Y., Ke, H.L., Huang, C.N., *et al.*, 2016. Predictors of positive bone metastasis in newly diagnosed prostate cancer patients. *Asian Pacific J. Cancer Prev.* 17: 1187–1191. doi:10.7314/APJCP.2016.17.3.1187
- Coppock, H.A., White, A., Aplin, J.D., & Westwood, M., 2004. Matrix metalloprotease-3 and -9 proteolyze insulin-like growth factor-binding protein-1. *Biol. Reprod.* 71: 438–443. doi:10.1095/biolreprod.103.023101
- Coyne, K.S., Sexton, C.C., Thompson, C.L., Milsom, I., Irwin, D., Kopp, Z.S., *et al.*, 2009. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: Results from the epidemiology of LUTS (EpiLUTS) study. *BJU Int.* 104: 352–360. doi:10.1111/j.1464-410X.2009.08427.x
- Cui, N., Hu, M., & Khalil, R.A., 2017. Biochemical and Biological Attributes of Matrix Metalloproteinases, 1st ed, Progress in Molecular Biology and Translational Science. Elsevier Inc. doi:10.1016/bs.pmbts.2017.02.005
- da Silva, H.B., Amaral, E.P., Nolasco, E.L., de Victo, N.C., Atique, R., Jank, C.C., *et al.*, 2013. Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. *Prostate Cancer* 2013: 1–23. doi:10.1155/2013/920612
- Dai, C., Heemers, H., & Sharifi, N., 2017. Androgen signaling in prostate cancer. *Cold Spring Harb. Perspect. Med.* 7. doi:10.1101/cshperspect.a030452

- Danarto, R., Astuti, I., Umbas, R., & Haryana, S.M., 2019. Urine miR-21-5p and miR-200c-3p as potential non-invasive biomarkers in patients with prostate cancer. *Turkish J. Urol.* 46: 26–30. doi:10.5152/tud.2019.19163
- Dong, Z., Bonfil, R.D., Chinni, S., Deng, X., Trindade Filho, J.C., Bernardo, M., *et al.*, 2005. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. *Am. J. Pathol.* 166: 1173–1186. doi:10.1016/S0002-9440(10)62337-1
- Eedunuri, V.K., Rajapakshe, K., Fiskus, W., Geng, C., Chew, S.A., Foley, C., *et al.*, 2015. miR-137 targets p160 steroid receptor coactivators SRC1, SRC2, and SRC3 and inhibits cell proliferation. *Mol. Endocrinol.* 29: 1170–1183. doi:10.1210/me.2015-1080
- Egevad, L., Delahunt, B., Srigley, J.R., & Samaratunga, H., 2016. International Society of Urological Pathology (ISUP) grading of prostate cancer – An ISUP consensus on contemporary grading 433–435. doi:10.1111/apm.12533
- Eiseler, T., Döppler, H., Yan, I.K., Goodison, S., & Storz, P., 2009. Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. *Breast Cancer Res.* 11: 1–12. doi:10.1186/bcr2232
- Ferraldeschi, R., Welti, J., Luo, J., Attard, G., & De Bono, J.S., 2014. Targeting the androgen receptor pathway in castration-resistant prostate cancer: Progresses and prospects. *Oncogene* 34: 1745–1757. doi:10.1038/onc.2014.115
- Fleshner, K., Carlsson, S. V., & Roobol, M.J., 2017. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. *Nat. Rev. Urol.* 14: 26–37. doi:10.1038/nrurol.2016.251
- Fouad, H., Salem, H., Ellakwa, D.E.S., & Abdel-Hamid, M., 2019. MMP-2 and MMP-9 as prognostic markers for the early detection of urinary bladder cancer. *J. Biochem. Mol. Toxicol.* 33. doi:10.1002/jbt.22275
- Fujimoto, N., Mizokami, A., Harada, S., & Matsumoto, T., 2001. Different expression of androgen receptor coactivators in human prostate. *Urology* 58: 289–294. doi:10.1016/S0090-4295(01)01117-7
- Furman, D., Campisi, J., Verdin, E., Carrera-bastos, P., Targ, S., Franceschi, C., *et al.*, 2019. across the life span. *Nat. Med.* 25. doi:10.1038/s41591-019-0675-0
- Gandaglia, G., Abdollah, F., Schiffmann, J., Trudeau, V., Shariat, S.F., Kim, S.P., *et al.*, 2014. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. *Prostate* 74: 210–216. doi:10.1002/pros.22742
- Gonzalez-Avila, G., Sommer, B., Mendoza-Posada, D.A., Ramos, C., Garcia-Hernandez, A.A., & Falfan-Valencia, R., 2019. Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. *Crit. Rev. Oncol. Hematol.* 137: 57–83. doi:10.1016/j.critrevonc.2019.02.010
- Graham, L., & Schweizer, M.T., 2016. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. *Med. Oncol.* 33.

doi:10.1007/s12032-016-0759-3

- Gregory, C.W., He, B., Johnson, R.T., Ford, O.H., Mohler, J.L., French, F.S., *et al.*, 2001. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. *Cancer Res.* 61: 4315–4319.
- Guo, H., Dai, Y., Wang, A., Wang, C., Sun, L., & Wang, Z., 2018. Association between expression of MMP-7 and MMP-9 and pelvic lymph node and para-aortic lymph node metastasis in early cervical cancer. *J. Obstet. Gynaecol. Res.* 44: 1274–1283. doi:10.1111/jog.13659
- Gupta, S., Gupta, A., Saini, A.K., Majumder, K., Sinha, K., & Chahal, A., 2017. Prostate cancer: How young is too young? *Curr. Urol.* 9: 212–215. doi:10.1159/000447143
- Hamberg, M., Backes, C., Fehlmann, T., Hart, M., Meder, B., Meese, E., *et al.*, 2016. MiRTargetLink—miRNAs, genes and interaction networks. *Int. J. Mol. Sci.* 17. doi:10.3390/ijms17040564
- Han, L., Lam, E.W.F., & Sun, Y., 2019. Extracellular vesicles in the tumor microenvironment: Old stories, but new tales. *Mol. Cancer* 18: 1–14. doi:10.1186/s12943-019-0980-8
- Hara, T., Miyazaki, H., Lee, A., Tran, C.P., & Reiter, R.E., 2008. Androgen Receptor and Invasion in Prostate Cancer 1128–1136. doi:10.1158/0008-5472.CAN-07-1929
- Harshman, L.C., & Taplin, M.E., 2013. Abiraterone acetate: Targeting persistent androgen dependence in castration-resistant prostate cancer. *Adv. Ther.* 30: 727–747. doi:10.1007/s12325-013-0050-3
- Hawinkels, L.J.A.C., Zuidwijk, K., Verspaget, H.W., de Jonge-Muller, E.S.M., Duijn, W. van, Ferreira, V., *et al.*, 2008. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. *Eur. J. Cancer* 44: 1904–1913. doi:10.1016/j.ejca.2008.06.031
- Heemers, H. V., Regan, K.M., Schmidt, L.J., Anderson, S.K., Ballman, K. V., & Tindall, D.J., 2009. Androgen Modulation of Coregulator Expression in Prostate Cancer Cells. *Mol. Endocrinol.* 23: 572–583. doi:10.1210/me.2008-0363
- Hood, J.L., San Roman, S., & Wickline, S.A., 2011. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. *Cancer Res.* 71: 3792–3801. doi:10.1158/0008-5472.CAN-10-4455
- Huang, H., 2018. Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: Recent advances. *Sensors (Switzerland)* 18: 5–7. doi:10.3390/s18103249
- Humphrey, P.A., 2012. Histological variants of prostatic carcinoma and their significance. *Histopathology* 60: 59–74. doi:10.1111/j.1365-2559.2011.04039.x

- Incorvaia, L., Badalamenti, G., Rini, G., Arcara, C., Fricano, S., Sferrazza, C., *et al.*, 2007. MMP-2, MMP-9 and activin a blood levels in patients with breast cancer or prostate cancer metastatic to the bone. *Anticancer Res.* 27: 1519–1525.
- Izumi, K., Lin, W.J., Miyamoto, H., Huang, C.K., Maolake, A., Kitagawa, Y., *et al.*, 2014. Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level. *J. Cancer Res. Clin. Oncol.* 140: 1413–1419. doi:10.1007/s00432-014-1681-8
- Kan, H.C., Hou, C.P., Lin, Y.H., Tsui, K.H., Chang, P.L., & Chen, C.L., 2017. Prognosis of prostate cancer with initial prostate-specific antigen > 1,000 ng/mL at diagnosis. *Onco. Targets. Ther.* 10: 2943–2949. doi:10.2147/OTT.S134411
- Katari, S.K., Pasala, C., Nalamolu, R.M., Vanadoth, U.N., Alexancer, S.P., Pakala, S.R., *et al.*, 2019. Trends of acute - phase dengue at a tertiary care hospital , 2018–2021. doi:10.4103/JCSR.JCSR
- Kementrian Kesehatan Republik Indonesia, 2015. Kanker Prostat. *Pandu. Penatalaksanaan Kanker Prostat* 47.
- Khazaei, Z., Sohrabivafa, M., Momenabadi, V., Moayed, L., & Goodarzi, E., 2019. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide prostate cancers and their relationship with the human development index. *Adv. Hum. Biol.* 9: 245. doi:10.4103/2321-8568.262891
- Kobayashi, T., Kim, H.J., Liu, X., Sugiura, H., Kohyama, T., Fang, Q., *et al.*, 2014. Matrix metalloproteinase-9 activates TGF- β and stimulates fibroblast contraction of collagen gels. *Am. J. Physiol. - Lung Cell. Mol. Physiol.* 306: 1006–1015. doi:10.1152/ajplung.00015.2014
- Koo, K.C., Park, S.U., Kim, K.H., Rha, K.H., Hong, S.J., Yang, S.C., *et al.*, 2015. Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels. *Prostate Int.* 3: 10–15. doi:10.1016/j.prn.2015.02.006
- Kumar, S.R., Kimchi, E.T., Manjunath, Y., Gajagowni, S., & Stuckel, A.J., 2020. RNA cargos in extracellular vesicles derived from blood serum in pancreas associated conditions. *Sci. Rep.* 10: 1–10. doi:10.1038/s41598-020-59523-0
- Larsson, P., Syed Khaja, A.S., Semenas, J., Wang, T., Sarwar, M., Dizeyi, N., *et al.*, 2020. The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1 α /pAKT in prostate cancer. *Int. J. Cancer* 146: 1686–1699. doi:10.1002/ijc.32607
- Leitzmann, M.F., & Rohrmann, S., 2012. Risk factors for the onset of prostatic cancer: Age, location, and behavioral correlates. *Clin. Epidemiol.* 4: 1–11. doi:10.2147/CLEP.S16747
- Liao, R.S., Ma, S., Miao, L., Li, R., Yin, Y., & Raj, G. V., 2013. Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. *Transl.*

- Androl. Urol.* 2: 187–196. doi:10.3978/j.issn.2223-4683.2013.09.07
- Lin, W.-Y., Chang, Y.-H., Lin, C.-L., Kao, C.-H., & Wu, H.-C., 2017. Erectile dysfunction and the risk of prostate cancer. *Oncotarget* 8: 52690–52698. doi:10.18632/oncotarget.17082
- Liu, B., Gu, X., Huang, T., Luan, Y., & Ding, X., 2017. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1. *Oncol. Rep.* 37: 201–208. doi:10.3892/or.2016.5277
- Lonard, D.M., Kumar, R., & O'Malley, B.W., 2010. Minireview: The SRC family of coactivators: An entrée to understanding a subset of polygenic diseases? *Mol. Endocrinol.* 24: 279–285. doi:10.1210/me.2009-0276
- Lonergan, P., & Tindall, D., 2011. Androgen receptor signaling in prostate cancer development and progression. *J. Carcinog.* 10. doi:10.4103/1477-3163.83937
- Luef, B., Handle, F., Kharraishvili, G., Hager, M., Rainer, J., Janetschek, G., *et al.*, 2016a. The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1. *Endocr. Relat. Cancer* 23: 495–508. doi:10.1530/ERC-16-0160
- Luef, B., Handle, F., Kharraishvili, G., Hager, M., Rainer, J., Janetschek, G., *et al.*, 2016b. The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1. *Endocr. Relat. Cancer* 23: 495–508. doi:10.1530/ERC-16-0160
- Masiello, D., Chen, S.Y., Xu, Y., Verhoeven, M.C., Choi, E., Hollenberg, A.N., *et al.*, 2004. Recruitment of β -catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. *Mol. Endocrinol.* 18: 2388–2401. doi:10.1210/me.2003-0436
- McBryan, J., Theissen, S.M., Byrne, C., Hughes, E., Cocchiglia, S., Sande, S., *et al.*, 2012. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. *Cancer Res.* 72: 548–559. doi:10.1158/0008-5472.CAN-11-2073
- Merriell, S.W.D., Funston, G., & Hamilton, W., 2018. Prostate Cancer in Primary Care. *Adv. Ther.* 35: 1285–1294. doi:10.1007/s12325-018-0766-1
- Mitterberger, M., Horningera, W., Aigner, F., Pinggera, G.M., Steppan, I., Rehdera, P., *et al.*, 2010. Ultrasound of the prostate. *Cancer Imaging* 10: 40–48. doi:10.1102/1470-7330.2010.0004
- Mochtar, C.A., Atmoko, W., Umbas, R., & Hamid, A.R.A.H., 2017. Prostate cancer detection rate in Indonesian men. *Asian J. Surg.* 41: 163–169. doi:10.1016/j.asjsur.2017.01.001
- Moirangthem, A., Bondhopadhyay, B., Mukherjee, M., Bandyopadhyay, A., Mukherjee, N., Konar, K., *et al.*, 2016. Simultaneous knockdown of uPA and MMP9 can reduce breast cancer progression by increasing cell-cell adhesion and modulating EMT genes. *Sci. Rep.* 6: 1–11. doi:10.1038/srep21903

- Mondal, S., Adhikari, N., Banerjee, S., Amin, S.A., & Jha, T., 2020. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview. *Eur. J. Med. Chem.* 194: 112260. doi:10.1016/j.ejmech.2020.112260
- Mottet, N., Bergh, R.C.N. Van Den, Vice-chair, P.C., Santis, M. De, Gillessen, S., Govorov, A., *et al.*, 2018. EAU-ESUR-ESTRO-SIOG Guidelines on Prostate Cancer/ Guias Europeas. *Eur. Assoc. Urol.* 2018 1–145.
- Munson, P.B., Hall, E.M., Farina, N.H., Pass, H.I., & Shukla, A., 2019. Exosomal miR-16-5p as a target for malignant mesothelioma. *Sci. Rep.* 9: 1–13. doi:10.1038/s41598-019-48133-0
- Oguić, R., Mozetič, V., Cini Tešar, E., Fučkar Čupić, D., Mustać, E., & Orević, G., 2014. Matrix metalloproteinases 2 and 9 immunoexpression in prostate carcinoma at the positive margin of radical prostatectomy specimens. *Patholog. Res. Int.* 2014. doi:10.1155/2014/262195
- Ohnishi, Y., Inoue, H., Furukawa, M., Kakudo, K., & Nozaki, M., 2012. Heparin-binding epidermal growth factor-like growth factor is a potent regulator of invasion activity in oral squamous cell carcinoma. *Oncol. Rep.* 27: 954–958. doi:10.3892/or.2011.1616
- Ozden, F., Saygin, C., Uzunaslana, D., Onal, B., Durak, H., & Aki, H., 2013. Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival. *J. Cancer Res. Clin. Oncol.* 139: 1373–1382. doi:10.1007/s00432-013-1453-x
- Park, J.H., Rasch, M.G., Qiu, J., Lund, I.K., & Egeblad, M., 2015. Presence of insulin-like growth factor binding proteins correlates with tumor-promoting effects of matrix metalloproteinase 9 in breast cancer. *Neoplasia (United States)* 17: 421–433. doi:10.1016/j.neo.2015.04.003
- Pegtel, D.M., & Gould, S.J., 2019. Exosomes. *Annu. Rev. Biochem.* 88: 487–514. doi:10.1146/annurev-biochem-013118-111902
- Qin, L., Liao, L., Redmond, A., Young, L., Yuan, Y., Chen, H., *et al.*, 2008. The AIB1 Oncogene Promotes Breast Cancer Metastasis by Activation of PEA3-Mediated Matrix Metalloproteinase 2 (MMP2) and MMP9 Expression. *Mol. Cell. Biol.* 28: 5937–5950. doi:10.1128/mcb.00579-08
- Qin, L., Wu, Y.L., Toneff, M.J., Li, D., Liao, L., Gao, X., *et al.*, 2014. NCOA1 directly targets M-CSF1 expression to promote breast cancer metastasis. *Cancer Res.* 74: 3477–3488. doi:10.1158/0008-5472.CAN-13-2639
- Raezadeh-Sarmazdeh, M., Do, L.D., & Hritz, B.G., 2020. Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics. *Cells* 9: 1–34. doi:10.3390/cells9051313
- Rana, K., Davey, R.A., & Zajac, J.D., 2014. Human androgen deficiency: Insights gained from androgen receptor knockout mouse models. *Asian J. Androl.* 16: 169–177. doi:10.4103/1008-682X.122590
- Reid, J.F., Sokolova, V., Zoni, E., Lampis, A., Pizzamiglio, S., Bertan, C., *et al.*,

2012. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. *Mol. Cancer Res.* 10: 504–515. doi:10.1158/1541-7786.MCR-11-0342
- Reza, H.S., Ali, Z., Tara, H., & Ali, B., 2020. Age-specific reference ranges of prostate-specific antigen in the elderly of Amirkola: A population-based study. *Asian J. Urol.* 1–6. doi:10.1016/j.ajur.2020.03.001
- Richardsen, E., Andersen, S., Melbø-Jørgensen, C., Rakaee, M., Ness, N., Al-Saad, S., *et al.*, 2019. MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer. *Sci. Rep.* 9: 1–9. doi:10.1038/s41598-018-36854-7
- Russano, M., Napolitano, A., Ribelli, G., Iuliani, M., Simonetti, S., Citarella, F., *et al.*, 2020. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: The potentiality of blood samples. *J. Exp. Clin. Cancer Res.* 39: 1–13. doi:10.1186/s13046-020-01601-2
- Saini, S., 2016. PSA and beyond: alternative prostate cancer biomarkers. *Cell. Oncol.* 39: 97–106. doi:10.1007/s13402-016-0268-6
- Shah, K., Gagliano, T., Garland, L., Hanlon, T.O., Bortolotti, D., Gentili, V., *et al.*, 2020. Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing. *Oncogene* 6172–6189. doi:10.1038/s41388-020-01429-2
- Shahab, A.A., Soebadi, D.M., Djatisoesanto, W., Hardjowijoto, S., Soetojo, S., & Hakim, L., 2013. Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer. *Prostate Int.* 1: 23–30. doi:10.12954/pi.12003
- Shtivelman, E., Beer, T.M., & Evans, C.P., 2014. Molecular pathways and targets in prostate cancer. *Oncotarget* 5: 7217–7259. doi:10.18632/oncotarget.2406
- Silva, J., García, V., Zaballos, Á., Provencio, M., Lombardía, L., Almonacid, L., *et al.*, 2011. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. *Eur. Respir. J.* 37: 617–623. doi:10.1183/09031936.00029610
- Song, L.N., Silva, J., Koller, A., Rosenthal, A., Chen, E.I., & Gelmann, E.P., 2015. The tumor suppressor NKX3.1 is targeted for degradation by DYRK1B kinase. *Mol. Cancer Res.* 13: 913–922. doi:10.1158/1541-7786.MCR-14-0680
- St. John, J., Powell, K., Katie Conley-LaComb, M., & Chinni, S.R., 2012. TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression. *J. Cancer Sci. Ther.* 4: 94–101. doi:10.4172/1948-5956.1000119
- Tan, L.G., Tan, Y.K., Tai, B.C., Tan, K.M., Gauhar, V., Tiong, H.Y., *et al.*, 2017. Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml⁻¹. *Asian J. Androl.* 19: 286–290. doi:10.4103/1008-682X.168687

- Tanaka, N., Shimada, K., Nakagawa, Y., Hirao, S., Watanabe, S., Miyake, M., *et al.*, 2015. The optimal number of initial prostate biopsy cores in daily practice: A prospective study using the Nara Urological Research and Treatment Group nomogram. *BMC Res. Notes* 8: 4–9. doi:10.1186/s13104-015-1668-9
- Tawfik, A., 2015. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis. *Ont. Health Technol. Assess. Ser.* 15: 1–37.
- Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S., *et al.*, 2010. Integrative Genomic Profiling of Human Prostate Cancer. *Cancer Cell* 18: 11–22. doi:10.1016/j.ccr.2010.05.026
- Taylor, D.D., & Gercel-Taylor, C., 2008. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol. Oncol.* 110: 13–21. doi:10.1016/j.ygyno.2008.04.033
- Thangapazham, R., Saenz, F., Katta, S., Mohamed, A.A., Tan, S.H., Petrovics, G., *et al.*, 2014. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. *BMC Cancer* 14: 1–12. doi:10.1186/1471-2407-14-16
- Thomsen, F.B., Westerberg, M., Garmo, H., Robinson, D., Holmberg, L., Ulmert, H.D., *et al.*, 2020. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide , population-based register study. *PLoS One* 15: e0228447.
- Tokuhara, C.K., Santesso, M.R., De Oliveira, G.S.N., Ventura, T.M.D.S., Doyama, J.T., Zambuzzi, W.F., *et al.*, 2019. Updating the role of matrix metalloproteinases in mineralized tissue and related diseases. *J. Appl. Oral Sci.* 27: 1–14. doi:10.1590/1678-7757-2018-0596
- Trudel, D., Fradet, Y., Meyer, F., & Têtu, B., 2010. Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis. *Hum. Pathol.* 41: 1694–1701. doi:10.1016/j.humpath.2010.05.001
- Umezu, T., Ohyashiki, K., Kuroda, M., & Ohyashiki, J.H., 2013. Leukemia cell to endothelial cell communication via exosomal miRNAs. *Oncogene* 32: 2747–2755. doi:10.1038/onc.2012.295
- Vandooren, J., Van Den Steen, P.E., & Opdenakker, G., 2013. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. *Crit. Rev. Biochem. Mol. Biol.* 48: 222–272. doi:10.3109/10409238.2013.770819
- Vaupel, P., & Multhoff, G., 2020. Fatal Alliance of Hypoxia- / HIF-1 α -Driven Microenvironmental Traits Promoting Cancer Progression. *Adv. Exp. Med. Biol.* 169–176. doi:10.1007/978-3-030-34461-0
- Vincent Cavailles, R.M.-G.M.T.M.L., 2017. World Journal of Transplantation. *World J. Gastroenterol.* 23: 4480–4490. doi:10.5500/wjt.v1.i1.4
- Walsh, C.A., Qin, L., Tien, J.C.Y., Young, L.S., & Xu, J., 2012. The function of

- steroid receptor coactivator-1 in normal tissues and cancer. *Int. J. Biol. Sci.* 8: 470–485. doi:10.7150/ijbs.4125
- Wang, B.R., Chen, C.C., Zheng, R.H., Hu, J.C., & Ou, Y.C., 2018. Comparison of cancer detection between 18- and 12-core prostate biopsy in Asian patients with prostate-specific antigen levels of 4–20 ng/mL. *J. Chinese Med. Assoc.* 81: 1044–1051. doi:10.1016/j.jcma.2018.06.003
- Wang, L., Li, W., Li, K., Guo, Y., Liu, D., Yao, Z., *et al.*, 2018. The oncogenic roles of nuclear receptor coactivator 1 in human esophageal carcinoma. *Cancer Med.* 7: 5205–5216. doi:10.1002/cam4.1786
- Wang, L.H., Wu, C.F., Rajasekaran, N., & Shin, Y.K., 2019. Loss of tumor suppressor gene function in human cancer: An overview. *Cell. Physiol. Biochem.* 51: 2647–2693. doi:10.1159/000495956
- Wang, T., Jin, X., Liao, Y., Sun, Q., Luo, C., Wang, G., *et al.*, 2018. Association of NF- κ B and AP-1 with MMP-9 Overexpression in 2-Chloroethanol Exposed Rat Astrocytes. *Cells* 7: 96. doi:10.3390/cells7080096
- WHO, 2019. Indonesia Source GLOBOCAN 2018. *Int. Agency Res. Cancer* 256: 1–2.
- Xia, Y., Lian, S., Khoi, P.N., Yoon, H.J., Joo, Y.E., Chay, K.O., *et al.*, 2015. Chrysin inhibits tumor promoter-induced MMP-9 expression by blocking AP-1 via suppression of ERK and JNK pathways in gastric cancer cells. *PLoS One* 10: 1–16. doi:10.1371/journal.pone.0124007
- Xu, J., Wu, R.C., & O'Malley, B.W., 2009. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. *Nat. Rev. Cancer* 9: 615–630. doi:10.1038/nrc2695
- Xu, R., Rai, A., Chen, M., Suwakulsiri, W., Greening, D.W., & Simpson, R.J., 2018. Extracellular vesicles in cancer — implications for future improvements in cancer care. *Nat. Rev. Clin. Oncol.* 15: 617–638. doi:10.1038/s41571-018-0036-9
- Xu, Y., Chen, Q., Li, W., Su, X., Chen, T., Liu, Y., *et al.*, 2010. Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness. *Oncogene* 29: 3386–3397. doi:10.1038/onc.2010.90
- Yabluchanskiy, A., Ma, Y., Iyer, R.P., Michael, E., Lindsey, M.L., Yarbrough, W.M., *et al.*, 2014. Matrix Metalloproteinase-9 : Many Shades of Function in Cardiovascular Disease REVIEWS Matrix Metalloproteinase-9 : Many Shades of Function in Cardiovascular Disease. *Physiology* 391–403. doi:10.1152/physiol.00029.2013
- Yamamoto, K., Murphy, G., & Troeberg, L., 2015. Extracellular regulation of metalloproteinases. *Matrix Biol.* 44–46: 255–263. doi:10.1016/j.matbio.2015.02.007
- Yang, C.Q., Li, W., Li, S.Q., Li, J., Li, Y.W., Kong, S.X., *et al.*, 2014. MCP-1

- stimulates MMP-9 expression via ERK 1/2 and p38 MAPK signaling pathways in human aortic smooth muscle cells. *Cell. Physiol. Biochem.* 34: 266–276. doi:10.1159/000362997
- Yoo, T.K., Lee, K.S., Sumarsono, B., Kim, S.T., Kim, H.J., Lee, H.C., *et al.*, 2018. The prevalence of lower urinary tract symptoms in population aged 40 years or over, in South Korea. *Investig. Clin. Urol.* 59: 166–176. doi:10.4111/icu.2018.59.3.166
- Young, S.M., Bansal, P., Vella, E.T., Finelli, A., Levitt, C., & Loblaw, A., 2015. Guideline for referral of patients with suspected prostate cancer by family physicians and other primary care providers. *Can. Fam. Physician* 61: 33–39.
- Zarif, J.C., & Miranti, C.K., 2016. The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance. *Cell. Signal.* 28: 348–356. doi:10.1016/j.cellsig.2016.01.013
- Zhang, J., Li, S., Li, L., Li, M., Guo, C., Yao, J., *et al.*, 2015. Exosome and exosomal microRNA: Trafficking, sorting, and function. *Genomics, Proteomics Bioinforma.* 13: 17–24. doi:10.1016/j.gpb.2015.02.001
- Zhang, Y., Liu, Y., Liu, H., & Tang, W.H., 2019. Exosomes: Biogenesis, biologic function and clinical potential. *Cell Biosci.* 9: 1–18. doi:10.1186/s13578-019-0282-2
- Zhao, X., & Benveniste, E.N., 2008. Transcriptional Activation of Human Matrix Metalloproteinase-9 Gene Expression by Multiple Co-activators. *J. Mol. Biol.* 383: 945–956. doi:10.1016/j.jmb.2008.08.071
- Zheng, H., & Liu, J.F., 2017. Studies on the relationship between P13K/AKT signal pathway-mediated MMP-9 gene and lung cancer. *Eur. Rev. Med. Pharmacol. Sci.* 21: 753–759.
- Zhong, W. De, Han, Z.D., He, H.C., Bi, X.C., Dai, Q.S., Zhu, G., *et al.*, 2008. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. *Oncology* 75: 230–236. doi:10.1159/000163852
- Zhou, W., Fong, M.Y., Min, Y., Somlo, G., Liu, L., Palomares, M.R., *et al.*, 2014. Cancer-Secreted miR-105 destroys vascular endothelial barriers to promote metastasis. *Cancer Cell* 25: 501–515. doi:10.1016/j.ccr.2014.03.007